Circulating MicroRNA-21 is Downregulated in Patients with Metabolic Syndrome.

Author: Qing Fang HE ¹ ; Li Xin WANG ¹ ; Jie Ming ZHONG ¹ ; Ru Ying HU ¹ ; Le FANG ¹ ; Hao WANG ¹ ; Wei Wei GONG ¹ ; Jie ZHANG ¹ ; Jing PAN ¹ ; Min YU ¹
Author Information

1. Zhejiang Provincial Center for Disease Prevention and Control, Hangzhou 310051, Zhejiang, China.
Publication Type:Journal Article
MeSH: Adult; Aged; Down-Regulation; Female; Humans; Male; Metabolic Syndrome; blood; etiology; genetics; MicroRNAs; blood; genetics; metabolism; Middle Aged; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors
From: Biomedical and Environmental Sciences 2016;29(5):385-389
CountryChina
Language:English
Abstract: The microRNA-21 (miR-21) is known to play a major role in cancer progression; however, its function in the cardiovascular system appears to be even more complex and conflicting. To characterize miR-21 expression in the plasma of individuals with or without metabolic syndrome (MetS), 58 MetS cases and 96 non-MetS controls were investigated. Expression levels of miR-21 were significantly decreased in the circulation of MetS subjects (OR=0.52, 95% CI: 0.29-0.92) compared with that of non-MetS subjects. Body mass index (BMI) and the number of MetS components had a negative correlation with the level of miR-21, whereas age was inversely related to the level of miR-21. No significant difference was detected in miR-21 levels between the sexes (P=0.056). MiR-21 might be a negative regulating factor in MetS.